Effect Of Immunophenotyping On Prognosis Of Multiple Myeloma Patients Treated With Bortezomib As Main Treatment

Objective To investigate the effect of immunophenotyping on the prognosis of multiple myeloma(MM)patients treated with a bortezomib-containing regimen as main treatment.Methods This study retrospectively analyzed 76 MM patients and explored the prognostic significance of CD45,CD56 expression and other factors including international staging system(ISS),age,sex,immunoglobulin typing,myeloma cell proportions,hemoglobin,albumin,lactate dehydrogenase,creatinine,blood calcium,β2-microglobulin on PFS and OS in MM patients treated with a bortezomib-containing regimen.Results Univariate analysis showed that statistical difference of the median PFS(12 vs.19 months)and median OS(19 vs.23 months)was significant in the group of CD45 positive and negative expression in MM patients(respectively,P < 0.001,P = 0.001);the median PFS(14 vs.20.5 months)and median OS(16 vs.24.5 months)for MM patients with hemoglobin(Hb)<100 g/L and Hb> 100 g/L were statistically significant(respectively,P = 0.014,P = 0.026);the median PFS(13 vs.18 months)and median OS(14 vs.24 months)for MM patients with albumin(ALB)<35 g/L and ALB>35 g/L were statistically significant(respectively,P = 0.004,P = 0.008),and in female patients with MM,median PFS(13 vs.19 months,P = 0.008)and median OS(16 vs.25 months,P=0.008)were lower than in male patients with MM.Median PFS(17 vs.14 months)and median OS(19 vs.20 months)in CD56 expression-positive MM patients had no statistically significant difference(P = 0.538,P = 0.498)compared to those with CD56-negative expression.Multivariate analysis suggested that female and CD45 positive expression had independent adverse prognostic impact on PFS(P = 0.002,Exp(B)0.230;P<0.001,Exp(B)0.158)and OS(P = 0.002,Exp(B)0.242;P =0.001,Exp(B)0.218)in MM patients.Conclusion CD45 positive and female are important prognostic factors in MM patients treated with a bortezomib-containing regimen.